Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?
Akitsugu Sueki, Eriko Suzuki, Hitoshi Takahashi, Jun Ishigooka Department of Neuropsychiatry, Tokyo Women’s Medical University, Tokyo, Japan Purpose: In this prospective study, we examined whether early reduction in depressive symptoms predicts later remission to duloxetine in the treatm...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e80886a541504caf9029aadc27c762a4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e80886a541504caf9029aadc27c762a4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e80886a541504caf9029aadc27c762a42021-12-02T11:33:15ZDoes early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?1178-2021https://doaj.org/article/e80886a541504caf9029aadc27c762a42016-05-01T00:00:00Zhttps://www.dovepress.com/does-early-improvement-in-depressive-symptoms-predict-subsequent-remis-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Akitsugu Sueki, Eriko Suzuki, Hitoshi Takahashi, Jun Ishigooka Department of Neuropsychiatry, Tokyo Women’s Medical University, Tokyo, Japan Purpose: In this prospective study, we examined whether early reduction in depressive symptoms predicts later remission to duloxetine in the treatment of depression, as monitored using the Montgomery–Asberg Depression Rating Scale (MADRS). Patients and methods: Among the 106 patients who were enrolled in this study, 67 were included in the statistical analysis. A clinical evaluation using the MADRS was performed at weeks 0, 4, 8, 12, and 16 after commencing treatment. For each time point, the MADRS total score was separated into three components: dysphoria, retardation, and vegetative scores. Results: Remission was defined as an MADRS total score of ≤10 at end point. From our univariate logistic regression analysis, we found that improvements in both the MADRS total score and the dysphoria score at week 4 had a significant interaction with subsequent remission. Furthermore, age and sex were significant predictors of remission. There was an increase of approximately 4% in the odds of remission for each unit increase in age, and female sex had an odds of remission of 0.318 times that of male sex (remission rate for men was 73.1% [19/26] and for women 46.3% [19/41]). However, in the multivariate model using the change from baseline in the total MADRS, dysphoria, retardation, and vegetative scores at week 4, in which age and sex were included as covariates, only sex retained significance, except for an improvement in the dysphoria score. Conclusion: No significant interaction was found between early response to duloxetine and eventual remission in this study. Sex difference was found to be a predictor of subsequent remission in patients with depression who were treated with duloxetine, with the male sex having greater odds of remission. Keywords: antidepressant, early response, sex difference, serotonin–noradrenalin reuptake inhibitorSueki ASuzuki ETakahashi HIshigooka JDove Medical Pressarticleantidepressantearly responsegender differenceserotonin-noradrenalin reuptake inhibitorNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 1269-1273 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
antidepressant early response gender difference serotonin-noradrenalin reuptake inhibitor Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
antidepressant early response gender difference serotonin-noradrenalin reuptake inhibitor Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Sueki A Suzuki E Takahashi H Ishigooka J Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| description |
Akitsugu Sueki, Eriko Suzuki, Hitoshi Takahashi, Jun Ishigooka Department of Neuropsychiatry, Tokyo Women’s Medical University, Tokyo, Japan Purpose: In this prospective study, we examined whether early reduction in depressive symptoms predicts later remission to duloxetine in the treatment of depression, as monitored using the Montgomery–Asberg Depression Rating Scale (MADRS). Patients and methods: Among the 106 patients who were enrolled in this study, 67 were included in the statistical analysis. A clinical evaluation using the MADRS was performed at weeks 0, 4, 8, 12, and 16 after commencing treatment. For each time point, the MADRS total score was separated into three components: dysphoria, retardation, and vegetative scores. Results: Remission was defined as an MADRS total score of ≤10 at end point. From our univariate logistic regression analysis, we found that improvements in both the MADRS total score and the dysphoria score at week 4 had a significant interaction with subsequent remission. Furthermore, age and sex were significant predictors of remission. There was an increase of approximately 4% in the odds of remission for each unit increase in age, and female sex had an odds of remission of 0.318 times that of male sex (remission rate for men was 73.1% [19/26] and for women 46.3% [19/41]). However, in the multivariate model using the change from baseline in the total MADRS, dysphoria, retardation, and vegetative scores at week 4, in which age and sex were included as covariates, only sex retained significance, except for an improvement in the dysphoria score. Conclusion: No significant interaction was found between early response to duloxetine and eventual remission in this study. Sex difference was found to be a predictor of subsequent remission in patients with depression who were treated with duloxetine, with the male sex having greater odds of remission. Keywords: antidepressant, early response, sex difference, serotonin–noradrenalin reuptake inhibitor |
| format |
article |
| author |
Sueki A Suzuki E Takahashi H Ishigooka J |
| author_facet |
Sueki A Suzuki E Takahashi H Ishigooka J |
| author_sort |
Sueki A |
| title |
Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| title_short |
Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| title_full |
Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| title_fullStr |
Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| title_full_unstemmed |
Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| title_sort |
does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine? |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/e80886a541504caf9029aadc27c762a4 |
| work_keys_str_mv |
AT suekia doesearlyimprovementindepressivesymptomspredictsubsequentremissioninpatientswithdepressionwhoaretreatedwithduloxetine AT suzukie doesearlyimprovementindepressivesymptomspredictsubsequentremissioninpatientswithdepressionwhoaretreatedwithduloxetine AT takahashih doesearlyimprovementindepressivesymptomspredictsubsequentremissioninpatientswithdepressionwhoaretreatedwithduloxetine AT ishigookaj doesearlyimprovementindepressivesymptomspredictsubsequentremissioninpatientswithdepressionwhoaretreatedwithduloxetine |
| _version_ |
1718395854510882816 |